Correlating EGFR Expression with Receptor-Binding Properties and Internalization of 64Cu-DOTA-Cetuxi...
Correlating EGFR Expression with Receptor-Binding Properties and Internalization of 64Cu-DOTA-Cetuximab in 5 Cervical Cancer Cell Lines
About this item
Full title
Author / Creator
Publisher
United States: Soc Nuclear Med
Journal title
Language
English
Formats
Publication information
Publisher
United States: Soc Nuclear Med
Subjects
More information
Scope and Contents
Contents
The anti-epidermal growth factor receptor (anti-EGFR) antibody cetuximab is clinically approved for the treatment of EGFR-expressing metastatic colorectal cancer and advanced head and neck cancer. Overexpression of EGFR has also been found in more than 70% of carcinomas of the cervix. The overall goal of this study was to determine whether (64)Cu-1...
Alternative Titles
Full title
Correlating EGFR Expression with Receptor-Binding Properties and Internalization of 64Cu-DOTA-Cetuximab in 5 Cervical Cancer Cell Lines
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4277815
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4277815
Other Identifiers
ISSN
0161-5505
E-ISSN
1535-5667
DOI
10.2967/jnumed.108.052316
